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Abstract
Furin, one of the members of the family of proprotein convertases (PCs), ubiquitously expressed as a type I mem-
brane-bound proteinase, activates several proteins that contribute to tumor progression. In vitro studies using cancer
cell lines and clinical specimens demonstrated that furin processes important substrates such as insulin-like growth
factor 1 receptor (IGF-1R) and transforming growth factor β, leading to increased tumor growth and progression.
Despite the numerous studies associating furin with tumor development, its effects in preclinical models has not been
comprehensively studied. In this study, we sought to determine the protumorigenic role of furin in vivo after a two-
stage chemical carcinogenesis protocol in transgenic mice in which furin expression was targeted to the epidermal
basal layer. We found that processing of the PC substrate IGF-1R and the proliferation rate of mouse epidermis was
enhanced in transgenic mice when compared with their WT counterparts. Histopathologic diagnoses of the tumors
demonstrated that furin transgenic mice (line F47) developed twice as many squamous carcinomas as the control,
WT mice (P< .002). Similarly, tumors cells from transgenic mice were able to process PC substrates more efficiently
than tumor cells fromWT mice. Furthermore, furin expression resulted in a higher SCC volume in transgenic mice as
well as an increase in the percentage of high-grade SCC, including poorly differentiated and spindle cell carcinomas.
In conclusion, expression of furin in the basal layer of the epidermis increased tumor development and enhanced
tumor growth, supporting the consideration of furin as a potential target for cancer treatment.
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Introduction
The family of proprotein convertase (PC) is composed of a group of
serine proteinases implicated in regulating a broad range of complex
physiological and pathologic processes [1,2] by proteolytic activation
of precursor proteins. Nine members have already been identified,
including PC1/3, PC2, furin, PC4, PC5/6, PACE4, PC7, SKI-1/S1P,
and PCSK9 [3–5]. Most of these enzymes exert their functions by
processing numerous precursor protein substrates cleaving them at basic
residues within the motif (K/R)-(X)n-(K/R), where n = 0, 2, 4, or 6 and
where K is lysine, R is arginine, and X is any amino acid except cysteine.
Some of the PC protein substrates such as growth factors and their
cognate receptors, metalloproteinases, and adhesion molecules are
highly relevant to the neoplastic cell behavior [6–18]; therefore, many
attempts were made to explore the involvement of PCs in tumor growth
and development. Several studies demonstrated that PC1, PC2, furin,
PC5, PACE4, and PC7 are involved in regulating the biologic behavior
of various types of tumors [19–22]. Specifically, furin, a ubiquitously
expressed type I membrane-bound proteinase, has been reported to
be implicated in tumors of different origins. Furin messenger RNA
was elevated in lung non–small cell carcinoma but not in small cell
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carcinoma [23,24]. In human head and neck squamous cell carcinomas
(HNSCCs), furin expression and activity correlated with tumor pro-
gression based on the facts that furin messenger RNA and protein were
detected only in aggressive and metastasizing tumors [25,26].
Coexpression of insulin-like growth factor 1 receptor (IGF-1R) with
different PCs in furin-defective LoVo-C5 cells demonstrated that furin
is one of the major PCs responsible for pro–IGF-1R activation [8].
Stable expression of α1-antitrypsin Portland (PDX), a potent com-
petitive inhibitor of furin, resulted in the reduction of DNA synthesis,
anchorage-independent growth, and enhanced apoptotic phenotype
[27] and decreased tumorigenesis of xenotransplanted human tumor
cells [28]. Moreover, furin processed platelet-derived growth factor A
and vascular endothelial growth factor C. This regulatory ability was
tightly associated with tumorigenesis and metastasis in tumor cell mod-
els [29–31]. Furthermore, expression of its naturally occurring proseg-
ment inhibitor, ppFurin in cancer cell lines, contributed to decreased
matrix metalloproteinase MMP-9 activity, cell motility, migration, and
invasion of collagen [32] as well as activation of platelet-derived growth
factor A [33].
Our group found significant decrease or absence of tumorigenicity
after subcutaneous inoculation of tumor cells into severe combined
immunodeficient mice by transfecting PDX into HNSCC or astro-
cytoma cells [25,34]. The furin substrates IGF-1R, transforming growth
factor β (TGF-β), and membrane type 1–matrix metalloprotease were
not activated in PDX-expressing cells. This PDX-mediated tumor
suppression is mostly attributed to furin inhibition because tumor cells
expressing ppFur showed a similar loss or decrease in their tumorigenic
ability [28]. Furthermore, overexpression of furin caused a significant
increase in the invasive potential of HNSCC cells of low and moderate
aggressive potential in vitro and in vivo [27]. A synthetic furin inhibitor,
decanoyl-Arg-Val-Lys-Arg-chloromethyl-ketone (CMK) eliminated the
inhibitory effect of furin in the same tumor cells [27].
These successful in vitro and xenotransplantation experiments stim-
ulated the development of a mouse model to evaluate the effects of
PCs activity in vivo. Using a transgenic mouse model, we investigated
the function of another tumor-associated PC, PACE4 targeted to the
epidermis, in the processes of mouse skin squamous cell carcinoma
(SCC) growth and progression [35]. PACE4 transgenic mice developed
twice as many tumors as the wild-type (WT) counterpart and showed
significant disruptions of the basement membrane (BM), increasing
the invasive and metastatic behavior of the chemically induced SCCs.
However, PACE4’s role in tumor proliferation was less impressive.
Furin, on the other hand, has a prominent role in the processing of
IGF-1R, an antiapoptotic and proproliferative substrate. In this con-
text, its effects on tumor cell proliferation may be more pronounced
than PACE4’s. To study the role of furin in skin proliferation and
carcinogenesis, we developed another transgenic mouse model that
expresses furin in the epidermal basal layer and treated the mice with
a two-stage carcinogenesis protocol to ascertain the effect of this PC
on tumor development and progression.
Materials and Methods
Materials
12-O-Tetradecanoylphorbol-13-acetate (TPA) and 7, 12-dimethylbenz
(a)anthracene (DMBA) were purchased from Sigma-Aldrich (St Louis,
MO). FVB/N mice, 6 to 8 weeks of age, were purchased from Taconic
(Germantown, NY) and were used as WT controls.
Generation and Identification of K5-Furin Mice
The 3.2-kb full-length WT human furin complementary DNA
(cDNA) was excised from its parental pcDNA3.1 vector using PmeI
and EcoRV. The blunt-ended fragment was ligated into the SnaBI
site between the rabbit β-globin intron and the polyadenylation
sequences from a vector described previously [35] and inserted into
the K5 expression vector. Orientation and integrity of the insert were
confirmed by restriction analysis and sequencing. The K5-furin con-
struct was microinjected into the pronuclei of mouse embryos ob-
tained from FVB female mice mated with FVB male mice. DNA
was extracted from clipped tails as described [35]. Mice were geno-
typed by polymerase chain reaction (PCR) analysis of tail DNA using
primers specific for an internal fragment of furin and the junction
of furin with SV40 polyadenylation signal. The sequence of sense
primer was 5′GTGCTGTCTCATCGATTTGGCAA3′ and that
of antisense primer was 5′GCGGGCGGTGAGGCGACA3′ [36].
Tumor Induction Experiments
The two-stage carcinogenesis protocol was as follows: a single
100-nmol initiating dose of DMBA in 0.2 ml of acetone was applied
topically to the shaved dorsal skin of 6- to 8-week-old female mice.
One week after DMBA treatment, TPA (4 nmol) in 0.2 ml of ace-
tone was applied twice weekly to the skin for the duration of the
experiment (30 weeks). Tumor incidence and multiplicity were ob-
served weekly starting at 8 weeks of TPA promotion. The number
of mice per group was as follows: 33 WT mice, 28 K5-Furin line 47
(F47) mice, and 30 K5-Furin line 49 (F49) mice. Papillomas and
SCCs were recorded by gross observation and confirmed by histo-
logic analysis (see next paragraphs). Autopsies of carcinoma-bearing
mice were performed, and metastases in axial lymph nodes, lung, liver,
spleen, and other organs were recorded. All tumors were analyzed histo-
logically. SCCs were classified according to histopathologic grade [37].
Most SCCs were endophytic growths that invaded the dermis and
subcutaneous tissue. The differentiation patterns defining the histo-
pathologic grade were as follows: 1) grade 1 SCC, very well differen-
tiated with most of the tumor containing keratinizing cells and horny
pearls; 2) grade 2 SCC, moderately differentiated tumors in which up
to 50% of the tumor mass is formed by keratinizing cells; 3) grade 3
SCC or poorly differentiated tumors, containing less than 25% tumor
mass showing evidence of keratinization; and 4) grade 4 SCCs, very
poorly differentiated tumors or spindle cell carcinomas containing very
little or no histologic evidence of keratinization.
Keratinocyte Cultures and Western Blot Analyses
Primary epidermal keratinocytes from newborn mice were used to
determine expression levels of furin because of their suitability for
in vitro growth and further molecular analyses. Primary epidermal
keratinocytes were established in vitro as described [38,39]. Briefly,
1- to 3-day-old mice were euthanized, the skin was washed in a 1:10
solution of povidone-iodine (Betadine; Purdue Pharma, Stamford, CT),
and rinsed twice in sterile dH2O and twice in 70% alcohol. The skin was
removed and floated overnight on 2 ml of dispase (Dispase II, 25 U/ml;
BD Biosciences, Bedford, MA). The epidermis was separated from
the dermis, minced and incubated with 2 ml of 0.05% trypsin and
0.01% EDTA for 20 minutes at 37°C. DNase I (100 U) was added,
and the cells were mechanically dissociated by vigorous pipetting fol-
lowed by filtration through a 40-μm cell strainer (BD Biosciences).
The cells were washed in Dulbecco modified Eagle medium containing
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10% fetal calf serum and plated in low-Ca2+ keratinocyte growth
medium (Ca2+-free KGM 1:2; Cambrex, Walkersville, MD).
The keratinocytes grown in culture dishes were lysed and subjected
to furin Western blot analysis according to our previously reported
protocol [40]. The monoclonal antibody against furin (MON-152,
ALX-803-017; ALEXIS, Plymouth Meeting, PA) that recognizes
human furin was used as the primary antibody.
The processing of IGF-1R in keratinocytes was performed by
culturing keratinocytes to 80% to 90% confluence and subsequently
treating cells with furin convertase inhibitor, CMK (Val-Lys-Arg-
chloromethylketone, ALX-260-022; Enzo Life Sciences, Plymouth
Meeting, PA) at different concentrations. Twenty-four hours after
CMK treatment, the keratinocytes were lysed and subjected toWestern
blot analysis with polyclonal antibody against IGF-1Rβ (C-20, sc-713;
Santa Cruz Biotechnologies, Santa Cruz, CA). Primary tumors derived
from mice were also studied for expression of IGF-1Rβ and TGF-β
(no. 555052; BD Pharmingen, San Diego, CA) by Western blot
analysis. The quantification of Western blot results was performed by
using ImageJ developed by the National Institutes of Health.
Analysis of Epidermal Thickness and Cell Proliferation after
Treatment with TPA
To evaluate whether furin expression alters the proliferative ability of
the epidermis, we compared the proliferative response to the topically
applied phorbol ester TPA on the dorsal skin of WT and transgenic
animals. Groups of WT or furin transgenic mice (n = 5) were treated
with two applications of TPA (5 nmol) in acetone (acetone alone was
applied to a control group) separated by 48 hours and euthanized the
mice 48 hours after the last treatment. Paraffin sections were stained
with hematoxylin and eosin, and the skin thickness was measured with
a morphometry software that permits length measurements using
digital imaging (Image Pro-Plus; Media Cybernetics, Silver Spring,
MD). For analysis of cell proliferation, paraffin sections were used for
detecting the proliferation marker Ki67, using a rat monoclonal anti-
body (clone TEC-3; Dako, Carpinteria, CA) and a biotinylated goat
anti-rat IgG antibody (mouse adsorbed) together with an ABC detection
kit (Vector Elite; Vector, Burlingame, CA). Slides were mounted and
observed with a Nikon Optiphot (Nikon Instruments, Inc, Melville,
NY) with a Plan/Apo objective 20×, NA, 0.75, Nikon eyepiece ×10,
final magnification ×200. Epidermal cell proliferation index was deter-
mined in the interfollicular and intrafollicular epidermis by scanning the
slides using an Aperio CS ScanScope scanner (Aperio, Vista, CA) and
counting Ki67-positive and Ki67-negative epidermal basal keratinocytes
and determining the percentage of positive cells (three to five mice per
group; minimum number of cells counted/mouse was 500 per mouse).
Immunohistochemistry of Furin
Furin immunohistochemistry was performed using paraffin-
embedded normal skin, normal internal organs, and cutaneous tumors
fromWT and transgenic mice. All paraffin sections were subjected to a
previously published immunostaining protocol [37,41]. A monoclonal
antibody against furin that detects mouse and human furin protein
Figure 1. Generation of furin transgenic mice. (A) K5-Furin construct. (B) Real-time PCR quantification of the transgene present in several
founders. (C) PCR from DNA extracted from mouse tails, showing WT and two different animal founders that were used for most experi-
ments. (D) Western blot showing differential expression of furin protein in transgenic lines. Note the complete absence of furin expression
in the WT mice.
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(MON-148, ALX-803-015; ALEXIS) was used as a primary antibody
at 1:200. An avidin-biotin-peroxidase kit (Vectastain Elite; Vector)
was then used followed by the chromogen 3′, 3′-diaminobenzidine
to develop the immunostain. Negative controls were incubated in the
absence of the primary antibody with serum at the same protein con-
centration as the primary antibody. All sections were counterstained
with hematoxylin and mounted. Furin-positive cells were counted in
the interfollicular epidermis and expressed as furin-positive cells per
millimeter of epidermal BM. Basement membrane length was deter-
mined in furin-stained skin sections, and the furin-positive cells of
the respective interfollicular epidermal sector was counted using a mor-
phometry software that permits length measurements of digitalized
images (Image Pro-Plus; Media Cybernetics). BM length was deter-
mined in acetone- (control) and TPA-treated epidermis (three to five
mice per group; minimum BM length/mouse was 2 mm per section).
Gene Expression Analysis by Real-time PCR
RNA was extracted using the RNAqueous kit from Ambion (Austin,
TX). Quality was assessed using a RNA 6000 Nano LabChip on an
Agilent 2100 BioAnalyzer. Contaminating DNA from RNA prepara-
tions was removed using TURBO DNA-free (Ambion). RNA was
quantified using a Nanodrop (Nanodrop Technologies, Wilmington,
DE). RNA was reverse-transcribed (RT) using the M-MLV reverse
transcriptase (Ambion) and a mixture of anchored oligodT and random
decamers. For each sample, two RT reactions were performed with 100
and 25 ng of total RNA, respectively. Aliquots of cDNA were used for
quantitative PCR. Real-time PCRs were performed in duplicates using
an Applied Biosystems (Foster City, CA) 7900 HT instrument and
Applied Biosystems master mix. A 5-point, four-fold standard curve
was constructed from serial dilution with one of the samples to confirm
linearity of the RT step, PCR efficiency was close to 2, and to convert
the cycle threshold values into quantities. Cycling conditions were
95°C, 15 min, followed by 40 (two steps) cycles (95°C for 15 seconds
and 60°C for 60 seconds). The primers for human furin were as follows:
forward, GAGATTGAAAACACCAGCGAA; reverse, GCGGTGCC-
ATAGAGTACGAG; probe, 6fam-AACAACTATGGGACGCTGAC-
CAAGTTCAC-bhq1. For mouse furin, the primers were as follows:
forward, TCCTAGAGATTGAAAATACCAGTGAAG; reverse,
GGCTGTGCCATACAGAACGA; probe, 6fam-AACAACTATGG-
GACGCTGACCAAGTTCAC-bhq1. For mouse PACE4, the primers
were as follows: forward, AACCTCCTGCATCACCAACC; reverse,
AGCCGATTGGACTTCACCAT; probe, 6fam-ACGTGCA-
GCAATGCCGATGAGACT-bhq1. For mouse PC5, the primers
were as follows: forward, CTGATGGATGCCGAAGCC; reverse,
Figure 2. Immunhistochemical detection of furin expression in the basal layer of several epithelia of transgenic mice. Tail epidermis
(A), esophageal epithelium (B), oral epithelium (C), urothelium of the ureter (D), bronchial epithelium showing positive immunostain
in several basal cells (E), and biliary duct epithelium (F). Tissues are from the F47 mouse line. Immunohistochemistry and hematoxylin
counterstain, ×100.
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CTGTTTGGTCGAATGGTCTTGA (this was a SYBR Green assay,
whereas the others were TaqMan assays).
The following mouse primers were obtained from Applied Bio-
systems: Mm00478295_m1 for ppib, Mm00479023_m1 for PC1/3,
Mm00500981_m1 for PC2, Mm00801899_m1 for PC4, and
Mm00476621_m1 for PC7.
Statistical Analysis
Both two-sample t test and Wilcoxon tests were used to compare
tumor incidence and tumor volume. Wilcoxon test, a nonparametric
test, was used when sample size was small. The t test was used when
the sample size in each comparison group was greater than 30. P <
.05 was considered statistically significant. All statistical analyses were
performed using SAS 9.2 (SAS Institute Inc, Cary, NC).
Results
Generation and Characterization of Transgenic Mice
To study the effects of furin expression on the highly proliferative
epidermal basal cells, we subcloned the full-length human furin cDNA
into an expression vector containing bovine K5 promoter, which can
Figure 3. Ki67 detection in normal (untreated) mouse dorsal epidermis. A (WT), C (F47), and E (F49) show lower magnification images
(×100) of a sector of skin centered on a hair follicle showing the infundibulum or intrafollicular epidermis (*). B (WT), D (F47), and F (F49)
show at a higher magnification the interfollicular epidermis (×200). Note that the animal line F47 (C and D) exhibit more Ki67-positive cells
than the other two animal groups. (G) Quantification of Ki67-positive cells expressed as percentage of Ki67-positive basal keratinocytes in
the infundibulum and in the interfollicular epidermis (IFE). Ki67 immunohistochemistry and hematoxylin counterstain.
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direct furin expression to the basal skin keratinocytes. The construct
(Figure 1A) contains the bovine K5 promoter, followed by the first
intron of the rabbit β-globin gene to enhance the efficiency of transcrip-
tion, the full-length furin cDNA, and, finally, the polyadenylation sig-
nal from SV-40. A number of founders were produced, and mouse tail
DNA samples were used to determine the relative transgene dosage
using real-time PCR analysis. As shown in Figure 1B, lines 47, 49,
and 64 demonstrated relatively higher copy number of the furin trans-
gene as determined by real-time PCR. Because the transgene could only
be detected in the male progeny of line 64 and we only use female mice
for skin carcinogenesis experiments, lines 47 and 49 (called F47 and
F49) were used for all the following experiments. The two transgenic
lines were genotyped by PCR of genomic DNA using the primers
amplifying a DNA segment between 300 and 400 bp and a repre-
sentative genotyping experiment is shown in Figure 1C . Transgene
expression was confirmed by Western blot analysis of furin protein
expression. Furin protein was clearly expressed in the keratinocytes
from both transgenic mouse lines (molecular weight ∼100 kDa).
WT keratinocytes showed no or minimal furin expression (Figure 1D).
Densitometric evaluation of four different Western blots demon-
strated that line F47-derived epidermal keratinocytes expressed almost
twice as much furin as line F49-derived keratinocytes (ratio F47/F49 =
1.82 ± 0.44).
Effect of Furin Expression in the Epidermis
The distribution of furin expression in transgenic mice was further
analyzed by immunohistochemical (IHC) staining. In WT mouse,
furin expression was not seen; although occasionally, it could be
observed as minimal punctuate staining in the perinuclear cytoplasm
of basal epithelial cells in the epidermis and squamous mucosae (not
shown). Conversely, furin was clearly detected by IHC in most squa-
mous epithelia of transgenic mice (Figure 2). The location of furin was
cytoplasmic, predominately overexpressed in the epidermal basal layer
in both transgenic lines (Figure 2A). The cytoplasmic perinuclear
staining pattern of furin is in accordance with its known Golgi and
trans-Golgi network localization. In addition, the furin staining was
detected in the epithelial basal layer of the oral mucosa, esophagus,
exocervix, ureter, bronchus, and the epithelial cells of biliary ducts in
transgenic mice (Figure 2, B-F).
No gross phenotypic alterations were observed by the expression of
furin in transgenic mouse lines. Nevertheless, differences in cell pro-
liferation were detected in the transgenic epidermis when compared
with WT. The percent of Ki67-positive basal keratinocytes in the
infundibular (intrafollicular) epidermis was almost twice as high in
F47 compared with WT mice (P < .001) and approximately 20%
higher in F49 than in WT mice (P < .06). In the interfollicular epi-
dermis only the F47 basal keratinocyte Ki67 index was significantly
higher than in WT mice (P < .005) (Figure 3).
IGF-1R, one of the major substrates of furin, may be responsible
of the proproliferative effects of furin [8]. Thus, we examined the
processing of IGF-1R in mouse-derived epidermal primary keratino-
cyte cultures. Interestingly, the difference of IGF-1R processing in
keratinocytes derived from WT and F47 and F49 mice was mar-
ginal, suggesting that the endogenous furin expressed in WT keratino-
cytes efficiently processed pro IGF-1R. To observe a difference in
the activating ability of transgenic and WT derived keratinocytes, we
Figure 4. (A) Western blot analysis of IGF-1R processing in WT and transgenic primary keratinocyte cultures. The cells were challenged
in vitro with different doses of the PC inhibitor CMK to investigate the sensitivity of primary keratinocytes to IGF-1R cleavage inhibition
by CMK. A dose of 6 μM CMK was able to inhibit PC-mediated IGF-1R processing in WT keratinocytes, and the inhibitory effect was
directly proportional to the CMK dose up to 100 μM. The effect was noted by the increasing presence of IGF-1R precursor or proform
with increasing concentrations of CMK. Conversely, the CMK treatment failed to increase significantly the levels of the IGF-1R pre-
cursor in F47- and F49-derived cells. (B) Changes as depicted by plotting the ratios of densitometric evaluations of IGF-1R precursor to
processed bands.
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challenged the cells in vitro with different doses of the PC inhibi-
tor CMK to investigate the sensitivity of primary keratinocytes to
IGF-1R cleavage inhibition by CMK. As shown in Figure 4, a dose
as low as 6 μM CMK was able to inhibit PC-mediated IGF-1R pro-
cessing in WT keratinocytes, and the inhibitory effect was directly
proportional to the CMK dose up to a maximal effect at a dose of
100 μM CMK that displayed the maximal effect. The effect was
noted by the increasing presence of IGF-1R proform with increas-
ing concentrations of CMK (Figure 4). Conversely, the CMK treat-
ment, even at the highest dose, failed to increase the levels of the
IGF-1R proform in F47 and F49-derived cells, suggesting that the
high overexpression of furin in transgenic mouse keratinocytes over-
comes the inhibitor and the PC is able to activate the IGF-1R
substrate leaving little proform behind.
Short-term In Vivo Experiments
To evaluate differences in epidermal proliferation between WT and
transgenic mouse, we treated the skin topically with two doses of TPA
(separated by 48 hours) and analyzed furin expression and Ki67 index
by IHC 48 hours after the last TPA administration. Interestingly,
furin expression in F47 and F49 mouse epidermis was significantly
enhanced by the phorbol ester treatment (P < .001; Figure 5). Both
F47 and F49 epidermis showed an increase in the number of furin-
expressing keratinocytes after TPA application. This expression was
more intense in F47 than in F49 mice, whereas the number of posi-
tively stained basal keratinocytes was similar in both lines. In addition,
line F47 exhibited a much larger number of parabasal keratinocytes
that expressed this PC, and the intensity was also higher in this layer (Fig-
ure 5). As expected, the tumor promoter TPA dramatically stimulated
Figure 5. Immunohistochemistry of furin in dorsal mouse epidermis. A (WT), C (F47), and E (F49) depict acetone control epidermis.
C (F47) contains numerous furin-positive basal keratinocytes that are not obvious in the two other animal groups. B (WT), D (F47),
and F (F49) show epidermis treated with the phorbol ester (TPA). Although the untreated WT epidermis has negative (A), the TPA-treated
WT epidermis showed occasional moderate to marginal endogenous furin expression in the perinuclear area of some parabasal keratino-
cytes (B and inset). Untreated epidermis from F47 exhibits a large increase in furin-positive basal cells (C) that further increased together
with positive parabasal keratinocytes after TPA treatment (D). Epidermis from F49 also shows expression of furin in basal keratinocytes,
but as seen in the histogram (G), this increase is markedly smaller than the one detected in F47 mice. Asterisks indicate significantly
different changes when compared with the respective WT.
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the keratinocyte proliferation in the skin samples from all groups, ap-
proximately three- to four-fold compared with sham treated control
epidermis (not shown). Nevertheless, the increased proliferation rates
after TPA treatment were similar in WT and transgenic mice.
Skin Carcinogenesis Experiments
To investigate the role of furin during carcinogenesis, we treated
WT and transgenic animals using a two-stage carcinogenesis protocol.
Skin papillomas and carcinomas developed in both transgenic and WT
groups at approximately 11 and 18 weeks, respectively, suggesting that
furin drives a premature increased proliferation, leading to early tumor
development. More papillomas were noted in F47 and F49 mice than
in the WT animal group. Conversely, the prevalence of SCCs was
similar in these two groups until week 23, and it was in the last 7 weeks
(week 23 to week 30) that the number of SCC/mouse was higher in
the transgenic lines than in WT mice (Figure 6A), pointing to a furin-
dependent acceleration in both early development and conversion
rates. Thus, both transgenic lines, especially F47, developed a higher
number of SCCs than WT in almost each point recorded. The inci-
dence of malignant tumors in F47 mice, that is, the percentage of mice
with carcinomas, was consistently higher than inWTmice. The tumor
incidence of F49 and WT mice was similar. The mean number of
carcinomas per mouse at week 30 was approximately 1.00, 1.23, and
1.61 (P < .05) for WT, F49, and F47 mice, respectively. Histologic
diagnosis obtained at week 30 (histogram in Figure 6B) showed that
the SCC multiplicity of F47 (2.07 SCC/mouse; vs the gross count of
1.61 seen in Figure 6A) was double that of WT (1.03 SCC/mouse;
P < .002), whereas the increased carcinoma/mouse observed in F49
mice was not statistically significant. Interestingly, although most
SCC produced by the two-stage carcinogenesis protocol were low-grade
tumors, the percentage of high-grade SCC (SCC grades 3 and 4) was
7% and 11% of total SCC in the F47 and F49 groups, respectively,
compared with 3% for WT mice (pie charts in Figure 6C ). Tumor
volume in transgenic mice was consistently higher than that in WT
mice, especially in F49 mice, for example, at 30 weeks, the mean vol-
ume of tumors was 190 ± 35 mm3 in WT mice versus 390 ± 121 mm3
in the transgenic mice (P < .04). In line F47, the mean volume was
310 ± 188 mm3 at 30 weeks, but because of the dispersion of values,
it did not reach statistical significance (t test).
We were also able to detect processing of furin substrates in tumor
lysates obtained fromWT and transgenic mice. As shown in Figure 7,
the transgenic SCC cells, by and large, were able to process more
efficiently the precursors of IGF-IR and TGF-β than the WT-derived
tumor cells.
Figure 6. Results of skin chemical carcinogenesis experiments. (A) Prevalence of tumor multiplicity as expressed by SCC/mouse during
the course of the experiment as counted weekly and determined by the presence of large (>10 mm) infiltrating or ulcerated lesions of
the dorsal skin. (B) The number of SCC/mouse at the last time point (30 weeks) as determined by histopathologic analysis. (C) The pie
charts reflect the percentage of each type of SCC at the 30th week following the grading scale described in Materials and Methods.
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Expression of Other PCs after Transgenic Furin Expression
To evaluate the possible effect of forced transgene expression on
other PCs in epidermal cells, we evaluated the expression of PC RNA
using quantitative real-time PCR. As seen in Figure 8A, the transgene
(hFur) was expressed in normal murine keratinocytes derived from
animal lines F47 and F49 and naturally absent in WT keratinocytes.
The levels of expression in F47 keratinocytes was three-fold higher
than those in F49 cells, thus showing a similar trend as the protein
expression detected by Western blot analysis (Figure 1D). PC1 and
PC4 were undetectable in WT, F47, and F49 keratinocytes. In addi-
tion, the cultured normal keratinocytes from the three different animal
groups did not show major differences in PC transcript expression
levels. One exception is the relatively high levels of PC2 in the transgenic
keratinocytes. The difference with WT expression is significant and
could be due to longer Merkel cell survival in the transgenic cell
cultures. Expression of PC RNAs in SCCs derived from carcinogen-
treated mice showed a similar trend with undetectable PC1, PC2, and
PC4, whereas the other PCs showed little or no changewhen comparing
WT to transgenic tumors.
Discussion
Furin is a serine protease that is frequently overexpressed in several
human cancer cell lines and malignancies [24,26,27,36,42,43] includ-
ing several murine cell lines derived from skin tumors induced by
chemical carcinogenesis [44]. Its activity results in proteolytic cleavage
of substrates leading to activation of many cancer-related proteins
including important growth factors and receptors such as IGF-1 and
its receptor IGF-1R, TGF-β, etc. [8,30,45–47].
To evaluate the in vivo effects of furin on skin biology and tumori-
genesis, we developed two K5-Furin mouse lines (F47 and F49). Real-
time PCR and Western analyses showed that F47 mice expressed
approximately twice as much furin as F49 mice at the protein level.
IHC analysis of both lines revealed increased number of basal keratino-
cytes expressing furin. The enhanced furin expression was reflected in
higher levels of activated IGF-1R as demonstrated by Western blot
analysis. This increase was more obvious and significant in F47 than
in F49 mice. Similarly, the basal keratinocyte proliferation rate of the
epidermis in F47 mice was significantly elevated over the WT and
F49 counterparts. Interestingly, this difference was more prominent
and significant in the infundibulum or intrafollicular segment of the
epidermis than in the interfollicular epidermis. This difference is even
more noteworthy if one takes into account several reports pointing
to the hair follicle and, in particular, to the suprasebaceous compo-
nent of this epidermal appendix as the origin of nonmelanoma skin
neoplasia [48–50].
In a previous report, we found that another PC, PACE4, had a
pivotal role in enhancing mouse skin tumor development and invasion
[35]. Because PACE4 is localized extracellularly, it has easy access to
intercellular and matrix-associated substrates such as metalloproteases
and is able to enhance tumor cell invasion. Furin, however, might
have a more prominent role in activating intracellular cancer–related
substrates that may influence other cellular processes such as prolifera-
tion. This possible divergence in function is supported by our results
showing that keratinocytes derived from untreated transgenic mice
expressing furin in the epidermal basal layer as well as tumor cells de-
rived from transgenic animals were able to process IGF-1R and TGF-β.
As a consequence of increased growth factor processing, transgenic
Figure 7.Western blot analysis of mouse tumor lysates obtained at the 30th week. Processing of IGF-1R and TGF-β shows an increased
ability of SCC cells from K5-Furin mice to process these two furin substrates compared with a lower activation and larger accumulation
of the precursor or proform in WT tumor cells. Histograms show these changes as detected by densitometric quantification.
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epidermis showed a higher proliferative rate than control WT epider-
mal cells in vivo. Conversely, we were unable to detect differences in
processing of MT1-MMP and MT2-MMP in WT and transgenic
epidermal cells derived from the two animal lines F47 and F49 (not
shown). In a previous report [35], we demonstrated that K5-PACE4
keratinocytes were able to process membrane-type MMPs and have
an increased invasive ability, suggesting that furin and PACE4 may
exert different functions, despite their similar enzyme properties.
To demonstrate a causal relationship between furin expression and
increased tumorigenesis in vivo, we studied furin-overexpressing
transgenic and WT mice treated with a two-stage skin carcinogenesis
protocol. During the entire experimental period after the appearance
of benign tumors or papillomas, the mean number of papillomas/
mouse was higher in both transgenic mouse lines than in WT mice.
More importantly, the mean number of SCC/mouse showed a similar
tendency, in both lines at 30 weeks of treatment with the two-stage
carcinogenesis protocol; the number of carcinomas per animal was
higher than in WT mice, although this difference was most marked
in F47 mice. Moreover, the incidence of malignant tumors, which is
defined as the percentage of animals harboring carcinomas, was consis-
tently higher in transgenic mice. In addition, tumor multiplicity and
tumor volume were remarkably higher in transgenic mice when com-
pared withWTmice, probably reflecting the increased proliferative rate
evidenced in short-term in vivo experiments as well as by the increased
processing of IGF-1R and TGF-β seen in carcinomas derived from
transgenic mice.
Metastases in axial lymph nodes and lung were also higher in
number in transgenic mice than in WT mice. Because of the low
numbers of animals bearing metastases (mice had to be euthanized
at 30 weeks because of the large and numerous skin primary tumors),
the results were not statistically significant.
To assess a possible interference of the transgenic expression of furin
in epidermal keratinocytes, we conducted an evaluation of the RNA
expression of six other PCs in normal keratinocytes and SCCs derived
from WT, F47, and F49 mice. The quantitative real-time PCR results
showed that enforced furin expression had no or had minimal effect on
the levels of PACE4, PC5, and PC7, whereas PC1 and PC4 were
undetectable in both normal keratinocytes and SCC cells. PC2 was
detected at higher levels in transgenic keratinocytes than in their WT
counterparts. This effect may be due to a higher number or an en-
hanced survival of Merkel cells in the short-term cultures of transgenic
epidermal cells. Merkel cells are known to express high levels of PC2
[51]. Because this difference was not seen in the tumor cells where PC2
was undetectable in WT, F47, and F49 SCCs, it is doubtful that trans-
genic furin could have an enhancing effect on PC2 transcript expression
during tumor development.
The data indicate that increased furin expression enhanced tumor
development and growth without significantly affecting the expression
of other endogenous PCs. It is noteworthy that the higher prevalence
of SCCs in the transgenic line F47 versus line F49 correlated well with
the relatively higher expression of furin in basal keratinocytes of line
F47 as well with its increased baseline keratinocyte proliferation rate
and also with a higher expression of furin in the SCCs of line F47 when
compared with their counterparts in line F49, suggesting that there
might be a dose-response type effect between the transgene level of
expression and the susceptibility to skin chemical carcinogenesis.
Taken together, furin expression targeted in vivo to the epidermis re-
sulted in increased epidermal proliferation as well as increased cancer-
related substrate activation that had a protumorigenic effect that was
demonstrated by an increased susceptibility to carcinogen-induced skin
tumors as exemplified by an enhanced SCC multiplicity and tumor
volume. Because furin expression and activity are enhanced in lung
and head and neck cancers [24,26,27,36,42,43], these experimental
data further support the possible use of furin as a target in human
cancer treatment.
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